Table 2.
Difference in protein biomarker levels before and after statin therapy.
| 2a. All participants | |||
|---|---|---|---|
| Protein | T-statistic | P-Value | False discovery rate p-Value |
| TFPI | −6.38 | <0.0001 | <0.0001 |
| PON3 | −4.64 | <0.0001 | 0.0003 |
| LDLR | −4.45 | <0.0001 | 0.0004 |
| Gal-4 | 3.50 | 0.0006 | 0.01 |
| IGFBP-2 | 3.21 | 0.002 | 0.03 |
| PCSK9 | 2.72 | 0.007 | 0.10 |
| IL-1RT2 | 2.66 | 0.008 | 0.10 |
| Notch 3 | 2.57 | 0.01 | 0.10 |
| GDF-15 | 2.56 | 0.01 | 0.10 |
| BLM hydrolase | 2.56 | 0.01 | 0.10 |
| Ep-CAM | 2.52 | 0.01 | 0.10 |
| TIMP4 | 2.45 | 0.01 | 0.11 |
| COL1A1 | −2.32 | 0.02 | 0.14 |
| TFF3 | 2.31 | 0.02 | 0.14 |
| CHI3L1 | 2.19 | 0.03 | 0.16 |
| SHPS-1 | 2.13 | 0.03 | 0.16 |
| CCL16 | 2.13 | 0.03 | 0.16 |
| ST2 | 2.12 | 0.03 | 0.16 |
| CD163 | 2.12 | 0.03 | 0.16 |
| MMP-2 | 2.12 | 0.04 | 0.16 |
| SCGB3A2 | 2.09 | 0.04 | 0.16 |
| CNTN1 | 2.02 | 0.04 | 0.18 |
| CCL15 | 2.02 | 0.04 | 0.18 |
|
2b. Pitavastatin group | |||
| TFPI | −5.92 | <0.0001 | <0.0001 |
| PON3 | −3.79 | 0.0002 | 0.01 |
| IGFBP-2 | 3.15 | 0.002 | 0.06 |
| LDLR | −2.99 | 0.003 | 0.08 |
| IL-1RT2 | 2.73 | 0.007 | 0.13 |
| TFF3 | 2.36 | 0.02 | 0.30 |
| PCSK9 | 2.26 | 0.03 | 0.33 |
| ST2 | 2.16 | 0.03 | 0.35 |
| CCL16 | 2.14 | 0.03 | 0.35 |
| COL1A1 | −2.01 | 0.05 | 0.39 |
|
2c. Pravastatin group | |||
| Gal-4 | 3.50 | 0.0007 | 0.06 |
| LDLR | −3.29 | 0.001 | 0.06 |
| TFPI | −3.06 | 0.003 | 0.08 |
| PON3 | −2.74 | 0.007 | 0.16 |
| GDF-15 | 2.66 | 0.009 | 0.16 |
| BLM hydrolase | 2.10 | 0.04 | 0.53 |
Among all participants, protein biomarkers with a p-value of <0.05 and an absolute t-statistic >2 are shown. Of these protein biomarkers, 5 protein biomarkers had a false discovery rate p-value that was <0.05 (TFPI, PON3, LDLR, Gal-4, and IGFBP-2) and are shaded. Another 6 proteins trended toward a significant change with a false discovery rate p-value ≤0.10.
Abbreviations: TFPI, tissue factor pathway inhibitor; PON 3, paraoxonases 3; LDLR, low density lipoprotein receptor; Gal-4, galectin-4; IGFBP-2, insulin-like growth factor binding protein 2; PCSK9 proprotein convertase subtilisin/kexin type 9; IL-1RT2, interleukin-1 receptor, type II; Notch 3, neurogenic locus notch homolog protein 3; GDF-15, growth/differentiation factor 15; BLM hydrolase; bleomycin hydrolase; Ep-CAM, epithelial cell adhesion molecule; TIMP4; metalloproteinase inhibitor 4; COLIA1, collagen, type 1, alpha 1; TFF3, trefoil factor 3; CHI3LI, chitinase-3 like protein 1; SHPS-1, Src homology 2 (SH2) domain-containing protein tyrosine phosphatase substrate 1; CCL16, Chemokine (C-C motif) ligand 16; ST, ST2 protein; CD163, cluster of differentiation 163; MMP-2, matrix metalloproteinase-2; SCGB3A2, secretoglobulin family 3A member 2; CNTN1, contactin 1; CCL15, chemokine (C-C motif) ligand 15.
Among the pitavastatin group, protein biomarkers with a p-value of <0.05 and an absolute t-statistic >2 are shown. Of these protein biomarkers, 2 protein biomarkers had a false discovery rate p-value that was <0.05 (TFPI and PON3) and are shaded, whereas 2 other protein biomarkers trended toward a significant change with a false discovery rate p-value <0.10.
Abbreviations: TFPI, tissue factor pathway inhibitor; PON 3, paraoxonases 3; IGFBP-2, insulin-like growth factor binding protein 2; LDLR, low density lipoprotein receptor; IL-1RT2, interleukin-1 receptor, type II; TFF3, trefoil factor 3; PCSK9 proprotein convertase subtilisin/kexin type 9; ST2, ST2 protein; CCL16, Chemokine (C-C motif) ligand 16; COLIA1, collagen, type 1, alpha 1.
In the pravastatin group, protein biomarkers with a p-value of <0.05 and an absolute t-statistic >2 are shown. None of the protein biomarkers had a false discovery rate p-value of <0.05. There were 3 protein biomarkers which trended toward a significant change with a false discovery rate p-value <0.10.
Abbreviations: Gal-4, galectin-4; LDLR, low density lipoprotein receptor; TFPI, tissue factor pathway inhibitor; PON 3, paraoxonases 3; GDF-15, growth/differentiation factor 15; BLM hydrolase; bleomycin hydrolase.